Catalyst Memo
Know what the readout actually measures — before it prints.
You have read the press release and the abstract, and you still cannot tell whether the primary endpoint is the one that matters. Name the catalyst and get it back in writing, in plain English, in 3 business days.
No card required to ask. You get a reply within one business day with scope and price; the memo is delivered 3 business days after payment clears. Educational analysis of public data — not investment advice. See our editorial policy and disclosures.
What you get
- • Catalyst snapshot — what is being read out, when, and what the trial is actually measuring
- • What success looks like, in the endpoint the trial is powered for
- • What failure looks like, including the ways a "hit" can still disappoint
- • Endpoint risk — powering, multiplicity, surrogate vs clinical outcome
- • Safety and tolerability signals already visible in earlier phases
- • Dilution and financing risk into and after the event
- • What to watch next, with the primary sources to watch it in
Same structure as the public sample memo — read that first. If it is not worth $249 to you, do not buy this.
What this is not
- • No price target, no buy/sell/hold recommendation, and no position sizing
- • No personalized advice — the memo does not consider your finances or goals
- • No private or non-public information; sources are ClinicalTrials.gov, SEC filings, and FDA documents
- • No guarantee about the outcome of any readout, approval, or stock move
If you want someone to tell you whether to buy a stock, this is the wrong product and you should talk to a licensed adviser. What this does is close the gap between a clinical protocol and a decision you are making yourself.
How it works
- 1. Ask. Name the ticker or readout and what you are trying to decide. No card required.
- 2. Scope. You get a reply within one business day confirming it is answerable from public data, with the price and timing. Requests that cannot be answered honestly are declined, not invoiced.
- 3. Approve and pay. $249, invoiced. Nothing is charged before you approve the scope.
- 4. Delivered. The written memo lands 3 business days after payment clears, with every source linked so you can check the work.
Who writes it
Blane Jackson, DDS, MBA — a clinician and healthcare operator who reads trial documents for a living, not a portfolio manager. That is the relevant credential here: the memo is about what the evidence says, and explicitly not about what you should own.
4 memos a month
Each one is written by hand, so capacity is real rather than a countdown timer. If the month is full you will be told that in the reply, not after you have paid.
Educational use only. Not investment, tax, legal, or medical advice. Sources are public: ClinicalTrials.gov, SEC EDGAR, and FDA documents.